Studies on APP/PS1 mouse models of AD have shown that MCC950 is able to ameliorate cognitive function, presumably due to the drug’s ability reduce Aβ accumulation by stimulating its phagocytosis in vitro [110]. This evidence concerns the gene APP and Alzheimer disease.